Perspective Therapeutics CATX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -35.2%+6.3pp | -41.4%-4.4pp | -37.1%-5.8pp | -31.3%+1.8pp | -33.1%+10.2pp | |
| Return on invested capital | -44.3%+10.7pp | -55%+18.0pp | -73.1%-7.3pp | -65.7%-6.1pp | -59.6%+0.7pp | |
| Liquidity | ||||||
| Current ratio | 8.7×+3.6× | 5.2×-3.5× | 8.7×-6.4× | 15.1×-1.9× | 17×+4.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $3.35+19.6% | $2.80-14.0% | $3.26-8.9% | $3.58-9.0% | $3.93-12.8% | |
| Valuation | ||||||
| Market capitalization | $342.14M+33.2% | $204.43M-19.7% | $254.72M-10.2% | $283.55M+79.8% | $157.73M-26.8% | |
| Price / book | 1×+0.1× | 1×-0.1× | 1.1×0.0× | 1.1×+0.5× | 0.6×-0.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Perspective Therapeutics's profit margins?
- Perspective Therapeutics (CATX) runs a 33.1% gross margin and a -292.7% operating margin, with a -218.4% net margin.
- Where do Perspective Therapeutics's ratios come from?
- Every ratio is computed from Perspective Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
